These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 11108884)

  • 21. Suppression of ovarian function with the transdermally given synthetic progestin ST 1435.
    Laurikka-Routti M; Haukkamaa M; Lähteenmäki P
    Fertil Steril; 1992 Oct; 58(4):680-4. PubMed ID: 1426309
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antiprogestin inhibition of cell cycle progression in T-47D breast cancer cells is accompanied by induction of the cyclin-dependent kinase inhibitor p21.
    Musgrove EA; Lee CS; Cornish AL; Swarbrick A; Sutherland RL
    Mol Endocrinol; 1997 Jan; 11(1):54-66. PubMed ID: 8994188
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Variable effects of RU 486 on endometrial maintenance in the luteal phase extended by exogenous hCG.
    Croxatto HB; Salvatierra AM; Croxatto HD; Spitz IM
    Clin Endocrinol (Oxf); 1989 Jul; 31(1):15-23. PubMed ID: 2598478
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Progesterone antagonists and progesterone receptor modulators in the treatment of breast cancer.
    Klijn JG; Setyono-Han B; Foekens JA
    Steroids; 2000; 65(10-11):825-30. PubMed ID: 11108894
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of the progesterone receptor modulator VA2914 in a continuous low dose on the hypothalamic-pituitary-ovarian axis and endometrium in normal women: a prospective, randomized, placebo-controlled trial.
    Chabbert-Buffet N; Pintiaux-Kairis A; Bouchard P;
    J Clin Endocrinol Metab; 2007 Sep; 92(9):3582-9. PubMed ID: 17579200
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Interruption of endometrial maturation without hormonal changes by an antiprogesterone during the first half of luteal phase of the menstrual cycle: a contraceptive potential.
    Greene KE; Kettel LM; Yen SS
    Fertil Steril; 1992 Aug; 58(2):338-43. PubMed ID: 1633899
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of the antiprogesterone steroid RU 486 during midluteal phase in normal women.
    Schaison G; George M; Lestrat N; Reinberg A; Baulieu EE
    J Clin Endocrinol Metab; 1985 Sep; 61(3):484-9. PubMed ID: 2991322
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Morphologic response of endometrium to a progesterone receptor antagonist, RU486, in monkeys.
    Koering MJ; Healy DL; Hodgen GD
    Fertil Steril; 1986 Feb; 45(2):280-7. PubMed ID: 3949027
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Single monthly administration of the anti-progestagen Org 31710 in users of the 75 microg desogestrel progestagen-only pill: effects on pituitary-ovarian activity.
    van Heusden AM; Killick SR; Coelingh Bennink HJ; Fauser BC
    Hum Reprod; 2000 Mar; 15(3):629-36. PubMed ID: 10686210
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nestorone: a progestin with a unique pharmacological profile.
    Kumar N; Koide SS; Tsong Y; Sundaram K
    Steroids; 2000; 65(10-11):629-36. PubMed ID: 11108869
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effect of RU 486 administered during the early luteal phase on bleeding pattern, hormonal parameters and endometrium.
    Swahn ML; Bygdeman M; Cekan S; Xing S; Masironi B; Johannisson E
    Hum Reprod; 1990 May; 5(4):402-8. PubMed ID: 2113927
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Biological mechanisms underlying the clinical effects of mifepristone (RU 486) on the endometrium.
    Papp C; Schatz F; Krikun G; Hausknecht V; Lockwood CJ
    Early Pregnancy (Cherry Hill); 2000 Oct; 4(4):230-9. PubMed ID: 11742418
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Progesterone receptor antagonists Org 31710 and RU 486 increase apoptosis in human periovulatory granulosa cells.
    Svensson EC; Markström E; Shao R; Andersson M; Billig H
    Fertil Steril; 2001 Dec; 76(6):1225-31. PubMed ID: 11730755
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Interference with ovulation by sequential treatment with the antiprogesterone RU486 and synthetic progestin.
    Kekkonen R; Alfthan H; Haukkamaa M; Heikinheimo O; Luukkainen T; Lähteenmäki P
    Fertil Steril; 1990 Apr; 53(4):747-50. PubMed ID: 2108063
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antiproliferative effects of progesterone antagonists and progesterone receptor modulators on the endometrium.
    Chwalisz K; Brenner RM; Fuhrmann UU; Hess-Stumpp H; Elger W
    Steroids; 2000; 65(10-11):741-51. PubMed ID: 11108885
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A review of the endometrial histologic effects of progestins and progesterone receptor modulators in reproductive age women.
    Dinh A; Sriprasert I; Williams AR; Archer DF
    Contraception; 2015 May; 91(5):360-7. PubMed ID: 25596512
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of mifepristone on inhibition of ovulation and induction of luteolysis.
    Spitz IM; Croxatto HB; Lähteenmäki P; Heikinheimo O; Bardin CW
    Hum Reprod; 1994 Jun; 9 Suppl 1():69-76. PubMed ID: 7962472
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Non-competitive anti-oestrogenic actions of progesterone antagonists in primate endometrium: enhancement of oestrogen and progesterone receptors with blockade of post-receptor proliferative mechanisms.
    Neulen J; Williams RF; Breckwoldt M; Chwalisz K; Baulieu EE; Hodgen GD
    Hum Reprod; 1996 Jul; 11(7):1533-7. PubMed ID: 8671500
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antigestogens.
    Baird DT
    Br Med Bull; 1993 Jan; 49(1):73-87. PubMed ID: 8324617
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mechanism of action and clinical effects of antiprogestins on the non-pregnant uterus.
    Spitz IM; Robbins A
    Hum Reprod Update; 1998; 4(5):584-93. PubMed ID: 10027612
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.